Is it appropriate to prescribe Maltofer (iron polymaltose complex) off‑label to a 2‑year‑old child?

Maltofer (Iron Polymaltose Complex) Should Not Be Given to 2-Year-Old Children

The FDA-approved ferric maltol product (Maltofer/ACCRUFER) carries an explicit warning against use in children under 6 years of age due to fatal poisoning risk, and no intravenous iron polymaltose formulation is approved for pediatric use in Europe or the USA at age 2. 1

Critical Safety Concerns

The FDA label for ferric maltol explicitly states: "Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6" 1. This is not merely a precaution—it reflects documented mortality risk in young children.

Regulatory Status and Age Restrictions

• No approval exists for iron polymaltose complex in 2-year-olds in any jurisdiction
• The recent 2025 FDA pediatric approval for ferric maltol is limited to children ≥10 years 2
• The EU is evaluating extension only down to ≥12 years 2
• For intravenous iron formulations, iron sucrose is approved in the USA only from 2 years of age and older for chronic kidney disease-related anemia 3—but this refers to IV iron sucrose, not oral iron polymaltose

Evidence on Efficacy in Young Children

When iron polymaltose complex has been studied in young children:

• A 2021 meta-analysis found iron polymaltose is significantly less effective than ferrous sulfate for treating iron deficiency anemia, with clinically meaningful differences in hemoglobin (MD -0.81 g/dL, 95% CI -1.08 to -0.53; P < 0.001) and ferritin levels (MD -21.24,95% CI -39.26 to -3.23; P = 0.020) 4
• The evidence quality was rated as high certainty for the inferior efficacy 4
• Individual trials in children 6-18 months showed no efficacy advantage for iron polymaltose over ferrous sulfate 5

Safety Paradox

While some studies suggest iron polymaltose may have fewer gastrointestinal side effects 6, 4, this potential tolerability benefit is:

1. Offset by inferior efficacy, requiring longer treatment duration and potentially worse outcomes
2. Irrelevant given the lack of regulatory approval and explicit warnings for this age group
3. Overshadowed by the fatal overdose risk in children under 6 years

The Correct Approach for 2-Year-Olds

Use ferrous sulfate as first-line therapy:

• Dose: 3-6 mg/kg/day of elemental iron, divided into 1-2 doses
• If gastrointestinal side effects occur, switch to intermittent dosing (once or twice weekly) rather than changing formulations 7
• Alternative well-tolerated options include carbonyl iron (excellent bioavailability with high safety margin in overdose) 7

For prevention rather than treatment:

• Iron-fortified complementary foods and micronutrient powders are preferred 7
• Dietary iron from animal sources in developed countries 7

Common Pitfalls to Avoid

1. Do not prescribe iron polymaltose off-label to children under 10 years based on adult data or theoretical tolerability advantages
2. Do not assume "newer" iron formulations are safer—the overdose risk applies to all iron-containing products
3. Do not switch formulations for minor GI complaints—try intermittent dosing of ferrous sulfate first
4. Always counsel parents on safe storage away from children, regardless of formulation chosen

The answer is definitively no—iron polymaltose (Maltofer) should not be given off-label to 2-year-old children given the lack of approval, explicit safety warnings, and inferior efficacy compared to standard ferrous sulfate therapy.